The global limitation of targeting the intrinsic pathway is that the p53 tumor suppressor gene is mutated in up to half of human tumors [90], and mutations in other genes necessary for controlled cell death may render even more cancer cells resistant to these ICD therapies. The gene discussed is TP53; the disease is cancer.